1. Scrip
  2. >>Therapy Areas

Phase III Data ENLIVEN Pexidartinib’s Prospects But Liver Tox An Issue?

 
• By Ian Haydock

Phase III results for Daiichi Sankyo’s pexidartinib presented at ASCO provide new hope in a rare tumor type with no approved therapies, but hepatic toxicity also emerged as a safety issue in the study.

Digital illustration of Cancer cell in colour background
PEXIDARTINIB A NEW HOPE IN TGCT? • Source: Shutterstock

Daiichi Sankyo Co. Ltd. presented details of promising Phase III results for its developmental cancer drug pexidartinib at the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, that it says will be used to support a planned US NDA in a rare tumor type with no currently approved therapies.

One shadow lingering over the promising data however was hepatic toxicity, although the company does not appear too concerned

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.